- Report
- March 2025
- 150 Pages
Global
From €4420EUR$4,850USD£3,775GBP
- Report
- March 2025
- 175 Pages
Global
From €4092EUR$4,490USD£3,495GBP
- Report
- May 2024
- 128 Pages
Global
From €5923EUR$6,499USD£5,059GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3417EUR$3,750USD£2,919GBP
- Report
- January 2024
- 216 Pages
United States
From €3417EUR$3,750USD£2,919GBP
- Report
- January 2024
- 129 Pages
United States
From €3417EUR$3,750USD£2,919GBP
- Drug Pipelines
- November 2023
- 30 Pages
United States
From €2506EUR$2,750USD£2,141GBP
- Report
- August 2022
- 30 Pages
Global
From €2506EUR$2,750USD£2,141GBP
- Report
- February 2024
- 111 Pages
Global
From €4329EUR$4,750USD£3,697GBP
- Report
- April 2025
- 50 Pages
Global
From €2415EUR$2,650USD£2,063GBP
- Book
- July 2023
- 1568 Pages
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation. It is commonly used to treat arthritis, as well as other musculoskeletal conditions. It is available in both oral and injectable forms. Meloxicam is a member of the oxicam class of NSAIDs, which are known for their anti-inflammatory and analgesic properties. It works by blocking the production of certain chemicals in the body that cause inflammation and pain.
Meloxicam is a popular choice for treating pain and inflammation due to its effectiveness and relatively low risk of side effects. It is also cost-effective compared to other NSAIDs. Meloxicam is available in many countries, including the United States, Canada, and the United Kingdom.
Some companies that produce Meloxicam include Pfizer, Novartis, and Mylan. Show Less Read more
